{"prompt": "['Protocol VX18-445-109, Version 1.0', 'Page 9 of 60', 'Table 3-2', 'Study VX18-445-109: Treatment Period and Safety Follow-up Visit', 'TEZ/IVA Run-in', 'Safety', 'Period (4 weeks)', 'Treatment Period (24 weeks)', 'Follow-up', 'Visit', 'Day -14', '(28 7 Days', '(Day -15', 'After Last', 'Event/', 'Day -28', 'to', 'Day 15', 'Week 4', 'Week 8', 'Week 12', 'Week 16', 'Week 20', 'Week 24', 'ETT', 'Dose of', 'Assessment', '1 day', 'Day -3)', 'Day 1d', '3 days', '5 days', '5 days', '5 days', '5 days', '5 days', '5 days', 'Visitb', 'Study Drug)', 'Comments', 'Medications', 'Continuous from signing of ICF through completion of study participation', 'Completion of study', 'review', 'participation is defined in', 'Section 9.1.7.', 'Treatment and', 'Continuous from signing of ICF through completion of study participation', 'Completion of study', 'procedures review', 'participation is defined in', 'Section 9.1.7.', 'AEs and SAEs', 'Continuous from signing of ICF through completion of study participation', 'Completion of study', 'participation is defined in', 'Section 9.1.7.', 'AE: adverse event; CFQ-R: Cystic Fibrosis Questionnaire-Revised; ETT: Early Termination of Treatment; ICF: informed consent form; IVA: ivacaftor; SAE: serious adverse event; TEZ: tezacaftor', 'Vertex Pharmaceuticals Incorporated']['Protocol VX18-445-109, Version 1.0', 'Page 10 of 60', '4', 'TABLE OF CONTENTS', '1', 'Title Page', '1', '2', 'Protocol Synopsis', '2', '3', 'Schedule of Assessments', '5', '4', 'Table of Contents', '10', 'List of Tables', '13', 'List of Figures', '13', 'List of Abbreviations', '14', '5 Introduction', '16', '5.1', 'Background', '16', '5.2', 'Rationale for the Present Study', '16', '6', 'Study Objectives', '17', '6.1', 'Primary Objective', '17', '6.2', 'Secondary Objectives', '17', '7', 'Study Enppoints', '17', '7.1', 'Primary Endpoint', '17', '7.2', 'Key Secondary Endpoint', '17', '7.3', 'Secondary Endpoints', '17', '8', 'Study Population', '17', '8.1', 'Inclusion Criteria', '17', '8.2', 'Exclusion Criteria', '18', '9', 'Study Implementation', '19', '9.1', 'Study Design', '19', '9.1.1', 'Screening', '20', '9.1.1.1', 'Repetition of Screening Assessment(s', '21', '9.1.1.2', 'Rescreening', '21', '9.1.1.3', 'Extension of Screening Period Window', '21', '9.1.2', 'Tezacaftor/Ivacaftor Run-in Period', '21', '9.1.3', 'Treatment Period', '21', '9.1.4', 'Follow-up', '22', '9.1.5', 'Early Termination of Treatment', '22', '9.1.5.1', 'Discontinuation During the Run-in Period', '22', '9.1.5.2', 'Discontinuation During the Treatment Period', '22', '9.1.6', 'Lost to Follow-up', '23', '9.1.7', 'Completion of Study Participation', '23', '9.2', 'Method of Assigning Subjects to Treatment Groups', '23', '9.3', 'Rationale for Study Elements', '24', '9.3.1', 'Study Design', '24', '9.3.2', 'Study Population', '24', '9.3.3', 'Study Drug Dose', '24', '9.3.4', 'Rationale for Study Assessments', '24', '9.4', 'Study Restrictions', '25', '9.4.1', 'Prohibited Medications', '25', '9.5', 'Prior and Concomitant Medications', '25', '9.6 Administration', '26', 'Vertex Pharmaceuticals Incorporated']\n\n###\n\n", "completion": "END"}